Target Name: ZNF529
NCBI ID: G57711
Review Report on ZNF529 Target / Biomarker Content of Review Report on ZNF529 Target / Biomarker
ZNF529
Other Name(s): Zinc finger protein 529, transcript variant 1 | Zinc finger protein 529, transcript variant 2 | ZNF529 variant 1 | KIAA1615 | Zinc finger protein 529 (isoform a) | ZNF529 variant 2 | zinc finger protein 529 | ZN529_HUMAN | Zinc finger protein 529

ZNF529: A Potential Drug Target and Biomarker

Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in gene regulation and have been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. ZNF529, a ZF protein located in chromosome 16, is a potential drug target and biomarker for several diseases.

The ZNF529 gene encodes a protein that contains a zinc finger motif and is expressed in various tissues, including neurons, muscle cells, and the immune system. ZNF529 is a key regulator of gene expression and has been involved in the regulation of various cellular processes, including cell growth, differentiation, and survival.

Several studies have identified ZNF529 as a potential drug target due to its involvement in various diseases. For example, ZNF529 has been shown to be involved in the regulation of cancer cell growth and has been used as a therapeutic agent in several cancer treatments. In addition, ZNF529 has been linked to the development of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases, and has been shown to be involved in the regulation of neurotransmitter synthesis and release.

ZNF529 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, ZNF529 has been shown to be expressed in various types of cancer and has been used as a biomarker for the diagnosis and monitoring of cancer. In addition, ZNF529 has been linked to the development of neurodegenerative diseases and has been shown to be involved in the regulation of neurotransmitter synthesis and release in these diseases.

In addition to its potential clinical applications, ZNF529 has also been studied for its potential mechanisms of action. Several studies have shown that ZNF529 functions as a negative regulator of microRNA (miRNA) expression, which are small non-coding RNAs that play a crucial role in post-transcriptional gene regulation. These miRNAs can interact with ZNF529 and prevent it from regulating the expression of target genes, suggesting a potential mechanism of action for ZNF529.

Furthermore, ZNF529 has also been shown to interact with various protein partners, including casein kinase (CK) 2, a protein that is involved in the regulation of cellular processes such as cell adhesion, migration, and survival. These interactions suggest potential targets for future therapeutic interventions.

In conclusion, ZNF529 is a protein that has the potential to be a drug target and biomarker for several diseases. Its involvement in the regulation of gene expression and its potential interactions with protein partners make it an attractive target for future research and development. Further studies are needed to fully understand the mechanisms of action and potential therapeutic applications of ZNF529.

Protein Name: Zinc Finger Protein 529

Functions: May be involved in transcriptional regulation

The "ZNF529 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF529 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF529-AS1 | ZNF530 | ZNF532 | ZNF534 | ZNF536 | ZNF540 | ZNF541 | ZNF542P | ZNF543 | ZNF544 | ZNF546 | ZNF547 | ZNF548 | ZNF549 | ZNF550 | ZNF551 | ZNF552 | ZNF554 | ZNF555 | ZNF556 | ZNF557 | ZNF558 | ZNF559 | ZNF559-ZNF177 | ZNF560 | ZNF561 | ZNF561-AS1 | ZNF562 | ZNF563 | ZNF564 | ZNF565 | ZNF566 | ZNF566-AS1 | ZNF567 | ZNF568 | ZNF569 | ZNF56P | ZNF57 | ZNF570 | ZNF571 | ZNF571-AS1 | ZNF572 | ZNF573 | ZNF574 | ZNF575 | ZNF576 | ZNF577 | ZNF578 | ZNF579 | ZNF580 | ZNF582 | ZNF582-DT | ZNF583 | ZNF584 | ZNF585A | ZNF585B | ZNF586 | ZNF587 | ZNF587B | ZNF589 | ZNF592 | ZNF593 | ZNF594 | ZNF594-DT | ZNF595 | ZNF596 | ZNF597 | ZNF598 | ZNF599 | ZNF600 | ZNF603P | ZNF605 | ZNF606 | ZNF607 | ZNF608 | ZNF609 | ZNF610 | ZNF611 | ZNF613 | ZNF614 | ZNF615 | ZNF616 | ZNF618 | ZNF619 | ZNF620 | ZNF621 | ZNF622 | ZNF623 | ZNF624 | ZNF625 | ZNF625-ZNF20 | ZNF626 | ZNF627 | ZNF628 | ZNF629 | ZNF630 | ZNF638 | ZNF639 | ZNF641 | ZNF644